| __timestamp | Alnylam Pharmaceuticals, Inc. | Axsome Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 190249000 | 4279200 |
| Thursday, January 1, 2015 | 276495000 | 6776987 |
| Friday, January 1, 2016 | 382392000 | 21199860 |
| Sunday, January 1, 2017 | 390635000 | 19957616 |
| Monday, January 1, 2018 | 505420000 | 23495055 |
| Tuesday, January 1, 2019 | 655114000 | 53647067 |
| Wednesday, January 1, 2020 | 654819000 | 70244579 |
| Friday, January 1, 2021 | 792156000 | 58060725 |
| Saturday, January 1, 2022 | 883015000 | 57947447 |
| Sunday, January 1, 2023 | 1004415000 | 97944000 |
| Monday, January 1, 2024 | 1126232000 |
Data in motion
In the rapidly evolving world of biotechnology, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Alnylam Pharmaceuticals, Inc. and Axsome Therapeutics, Inc. have been at the forefront of this race since 2014. Over the past decade, Alnylam has consistently outpaced Axsome in R&D investment, with a staggering 428% increase from 2014 to 2023. In contrast, Axsome's R&D spending grew by approximately 2,187% during the same period, albeit from a much smaller base.
Alnylam's R&D expenses peaked in 2023, reaching nearly five times their 2014 levels, reflecting their aggressive pursuit of groundbreaking therapies. Meanwhile, Axsome's spending, though smaller in absolute terms, highlights their strategic focus on targeted innovations. This comparison underscores the diverse strategies within the biotech sector, where both scale and focus can drive success.
Research and Development Expenses Breakdown: Regeneron Pharmaceuticals, Inc. vs Alnylam Pharmaceuticals, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Alnylam Pharmaceuticals, Inc. and United Therapeutics Corporation
R&D Insights: How Alnylam Pharmaceuticals, Inc. and Intra-Cellular Therapies, Inc. Allocate Funds
Who Prioritizes Innovation? R&D Spending Compared for Alnylam Pharmaceuticals, Inc. and Incyte Corporation
Research and Development: Comparing Key Metrics for Alnylam Pharmaceuticals, Inc. and Exelixis, Inc.
Comparing Innovation Spending: Alnylam Pharmaceuticals, Inc. and Opthea Limited
R&D Spending Showdown: Alnylam Pharmaceuticals, Inc. vs Amneal Pharmaceuticals, Inc.
Comparing Innovation Spending: Alnylam Pharmaceuticals, Inc. and Xencor, Inc.
R&D Insights: How BeiGene, Ltd. and Axsome Therapeutics, Inc. Allocate Funds
Research and Development Expenses Breakdown: Exelixis, Inc. vs Axsome Therapeutics, Inc.
Comparing Innovation Spending: Axsome Therapeutics, Inc. and Iovance Biotherapeutics, Inc.
R&D Spending Showdown: Axsome Therapeutics, Inc. vs Dynavax Technologies Corporation